ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 168 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2017. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2019 | $27,338,000 | -16.3% | 430,627 | -8.5% | 0.37% | -15.2% |
Q1 2019 | $32,654,000 | +63.0% | 470,847 | +2.2% | 0.43% | +36.1% |
Q4 2018 | $20,038,000 | -44.0% | 460,852 | -1.7% | 0.32% | -34.0% |
Q3 2018 | $35,775,000 | +1.0% | 468,631 | +1.7% | 0.48% | -4.2% |
Q2 2018 | $35,410,000 | +40.0% | 460,648 | -7.1% | 0.50% | +41.6% |
Q1 2018 | $25,286,000 | +5.6% | 495,893 | -3.9% | 0.36% | +5.0% |
Q4 2017 | $23,937,000 | -13.7% | 516,113 | -0.9% | 0.34% | -29.8% |
Q3 2017 | $27,750,000 | -12.8% | 521,035 | +1.7% | 0.48% | -17.3% |
Q2 2017 | $31,827,000 | -24.8% | 512,430 | -17.9% | 0.58% | +84.8% |
Q1 2017 | $42,307,000 | +5.5% | 624,174 | +9.4% | 0.32% | +0.6% |
Q4 2016 | $40,099,000 | +14.7% | 570,321 | +15.7% | 0.31% | +18.9% |
Q3 2016 | $34,966,000 | – | 492,900 | – | 0.26% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |